Cochrane · systematic review · CD013876
Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction
O'Byrne, L, Webster, KE, MacKeith, S, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
8
No studies
6
Included studies
NR
No studies 6 · 42.9%Ungraded 0 · 0%Very low 8 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSystemic corticosteroids plus intranasal steroid/mucolytic/decongestant compared to no intervention for persistent post‐COVID‐19 olfactory dysfunction
Population: adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Psychophysical testing for recovery of sense of smell Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | RR 11 [0.7, 173.66] | 1 study · 18 participants | Very low Downgraded: risk of bias |
Disease‐related quality of life Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | no estimate extracted | NR | No studies |
Serious adverse events Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias |
Psychophysical testing for change in sense of smell Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias |
Generic quality of life Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | no estimate extracted | NR | No studies |
Presence of parosmia Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | no estimate extracted | NR | No studies |
Other adverse outcomes Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias |
Palmitoylethanolamide and luteolin compared to no intervention for the treatment of persistent post‐COVID‐19 olfactory dysfunction
Population: adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recovery of sense of smell (as Palmitoylethanolamide and luteolin vs no intervention | RR 0.24 [0.03, 1.67] | 1 study · 12 participants | Very low Downgraded: risk of bias |
Disease‐related quality of life Palmitoylethanolamide and luteolin vs no intervention | no estimate extracted | NR | No studies |
Serious adverse events Palmitoylethanolamide and luteolin vs no intervention | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias |
Change in sense of smell (as Palmitoylethanolamide and luteolin vs no intervention | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias |
Generic quality of life Palmitoylethanolamide and luteolin vs no intervention | no estimate extracted | NR | No studies |
Presence of parosmia Palmitoylethanolamide and luteolin vs no intervention | no estimate extracted | NR | No studies |
Other adverse outcomes Palmitoylethanolamide and luteolin vs no intervention | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias |